Stock · PODD · Healthcare
United States · Mid Cap · listed since 2007 · Revenue 12 mo. $3.1B
Price as of 11/06/2026
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Original text from the data provider
Summary
48.4 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €338.9M (2025), it supports €3.8B. The remaining €5.1B of the market value assume it grows 12.0% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.0%
no growth afterwards
Price to operating cash flow 19.9×, below its usual range.
Middle half of 16 quarters: 43.1× to 111.3×, median 54.1×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
2 more unchanged: Gross margin, EBIT margin
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 16.31% | 11.52% | Rank 70 |
| Return on capital (Greenblatt) | 22.87% | 32.55% | Rank 31 |
| EBIT margin | 17.50% | 18.31% | Rank 47 |
| FCF margin | 13.95% | 14.12% | Rank 48 |
| Gross margin | 71.63% | 60.99% | Rank 71 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 30.73% | 8.04% | Rank 91 |
| Earnings growth, 3 years per year | 273.83% | 5.44% | Rank 99 |
| Earnings growth, 5 years per year | 101.64% | 7.00% | Rank 99 |
| Sustainable growth (ROE × retained earnings) | 7.08% | 3.66% | Rank 85 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.35% | 2.90% | Rank 34 |
| FCF yield | 3.81% | 3.63% | Rank 52 |
| EV/saleslower is better | 3.78 | 4.03 | Rank 51 |
| EV/EBITlower is better | 21.60 | 21.73 | Rank 52 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −64.30% | 8.66% | Rank 1 |
| Share price, 6 months | −4.48% | 24.27% | Rank 11 |
| Share price, 3 months | 8.91% | 15.42% | Rank 32 |
| Distance from 52-week high | −57.70% | −7.35% | Rank 2 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −3.17% | 0.30% | Rank 81 |
| Change in share countlower is better | −2.71% | 0.00% | Rank 87 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −20.07% | 0.05% | Rank 1 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 47.49% | 48.40% | Rank 47 |
| Net debt/EBITDAlower is better | 0.66 | 1.11 | Rank 59 |
| Debt to equitylower is better | 0.69 | 0.48 | Rank 38 |
| Volatility, 1 yearlower is better | 45.09% | 31.42% | Rank 16 |
Ten years in figures
| Year | Revenue | EBIT margin | FCF, $M | Shares | Net debt, $M |
|---|---|---|---|---|---|
| 2016 | $367.0M | −2.9% | −6.2 | 57.3M | 195.9 |
| 2017 | $463.8M | −1.6% | −36.0 | 58.0M | 126.1 |
| 2018 | $563.8M | 4.9% | −126.5 | 61.0M | 478.1 |
| 2019 | $738.2M | 6.8% | −72.5 | 62.3M | 511.8 |
| 2020 | $904.4M | 5.7% | −82.5 | 65.9M | 96.1 |
| 2021 | $1.1B | 11.5% | −190.8 | 68.6M | 457.2 |
| 2022 | $1.3B | 2.9% | −38.3 | 69.9M | 808.9 |
| 2023 | $1.7B | 13.0% | 70.1 | 73.6M | 798.1 |
| 2024 | $2.1B | 14.9% | 305.4 | 73.9M | 468.6 |
| 2025 | $2.7B | 17.5% | 377.7 | 71.9M | 334.7 |
4 of 7 StockScorer Score rules met · How the score is built
Insulet Corporation mainly meets criteria in the Growth category. Result from 18 strategies checked.
Insulet Corporation is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Insulet Corporation.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 42.6 | 30.0 |
| P/B ratio | 7.0 | 4.8 |
| Return on equity (ROE) | 16.3% | 11.5% |
| Equity ratio | 47.5% | 48.4% |
| Debt-to-equity (D/E) | 0.69 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| PODD | Insulet Corporationthis page | |
| PEN | Penumbra Inc | locked |
| GKOS | Glaukos Corp | locked |
| ZBH | Zimmer Biomet Holdings Inc | Low4.5 |
| STE | STERIS plc | locked |
| DXCM | DexCom Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.